CanBas Co

CanBas Co FCF/Net Income

The Free Cash Flow to Net Income Ratio of CanBas Co (4575.T) as of Oct 18, 2026 is 108.80 %. In the previous year, Free Cash Flow to Net Income Ratio was 66.68 % — a change of 63.18% (higher).

FCF/Net Income

108.80 %

YoY

63.18%

Last updated:

Free Cash Flow to Net Income Ratio of CanBas Co is 2026 108.80 % . Free Cash Flow to Net Income Ratio of CanBas Co was 2025 66.68 % . It decreases by 63.18% higher compared to the previous year.

The CanBas Co FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2019
83.95 JPY
Jan 1, 2020
96.53 JPY
Jan 1, 2021
129.67 JPY
Jan 1, 2022
84.13 JPY
Jan 1, 2023
112.44 JPY
Jan 1, 2024
105.89 JPY
Jan 1, 2025
66.68 JPY
Jan 1, 2026
108.80 JPY
The CanBas Co FCF/Net Income history
YEARFCF/Net IncomeYoY
108.80 %+63.18%
66.68 %-37.03%
105.89 %-5.83%
112.44 %+33.65%
84.13 %-35.12%
129.67 %+34.33%
96.53 %+14.98%
83.95 %+4.13%
80.63 %+7.96%
74.68 %-28.03%
103.77 %-13.96%
120.62 %+72.44%
69.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co Ltd is a biotechnology company based in Numazu-shi, Japan, operating within the healthcare sector. The company has a small team of 12 employees and went public on September 17, 2009, with its ticker listed as 4575.T and ISIN JP3244570002. Its primary focus is on anticancer drug discovery research, which includes developing drug discovery concepts, selecting candidate compounds through method-based approaches, conducting simple animal studies, and analyzing basic data on anticancer drug candidates entering development. Additionally, CanBas engages in early clinical development activities, such as preclinical studies required before submitting applications for clinical trials and conducting the initial phases of clinical trials. The company maintains a website at https://www.canbas.co.jp/ for further information. CanBas operates as a private entity with a minimal workforce, emphasizing research and development in the early stages of anticancer drug development. It does not provide details on specific products, acquisitions, or financial figures beyond its IPO date and employee count. The company's headquarters are located in Numazu-shi, Shizuoka Prefecture, Japan, and it is listed on the Tokyo Stock Exchange. Its operations are centered around foundational research in oncology, aiming to contribute to the discovery and development of new anticancer treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Free Cash Flow to Net Income Ratio of CanBas Co is 108.80 % in 2026.

Free Cash Flow to Net Income Ratio of CanBas Co changed from 66.68 % to 108.80 %, representing a 63.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio CanBas Co since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's CanBas Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — CanBas Co

All Key Metrics — CanBas Co